Safety and Preliminary Efficacy of NXL-001 in Patients with Ischemic Stroke

NCTID	NCT06761183 (View at clinicaltrials.gov)
Description	This is a single-arm, open-label, single center, dose-escalation exploratory clinical study to evaluate the safety and tolerability of a single intracerebral injection of NXL-001, a NeuroD1 base gene therapy, in patients with chronic neuronal deficits from ischemic stroke. (Show More)
Development Status	Active
Indication	Ischemic Stroke
Disease Ontology Term	DOID:3526
Compound Name	NXL-001
Sponsor	Beijing Tiantan Hospital
Funder Type	Other
Recruitment Status	Not yet recruiting
Enrollment Count	9
Results Posted	Not Available

Target Gene/Variant	NeuroD1
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intracerebral
Drug Product Type	Viral vector
Target Tissue/Cell	Astrocyte
Delivery System	Viral transduction
Vector Type	AAV9
Editor Type	none
Dose 1	Dose escalation with 3 levels, unknown concentrations
Dose 2
Dose 3
Dose 4
Dose 5

No.of Trial Sites	1
Locations	China